Top

Published in:

01-03-2011 | Review

Clinical transplantation tolerance

Author: Kenneth A. Newell

Published in: Seminars in Immunopathology | Issue 2/2011

Abstract

Transplantation is the treatment of choice for many if not most causes of end-stage organ failure. Over 20,000 organ transplant procedures were performed in the USA in 2009 to treat patients with failed or failing kidneys, livers, hearts, lungs, and intestines, and there remain 85,000 individuals waiting on the transplant list. Currently, in the USA, there are over 170,000 individuals living with a transplanted organ. Virtually, all of these individuals receive maintenance immunosuppression in an attempt to maximize the function and survival of the transplanted organ. However, it is clear that the long-term use of immunosuppressive agents is associated with an extensive list of undesirable side effects that have the potential to limit the survival of the patient and transplanted organ as well as to compromise quality of life. Although the ability to induce reproducibly a state of robust, stable tolerance would address this problem, tolerance remains an infrequent event in clinical transplantation that is largely a consequence of chance. Factors limiting the broader investigation of clinical transplantation tolerance include the lack of therapeutic regimens known to favor tolerance in humans, the lack of validated assays or biomarkers predictive of tolerance, and concerns about the safety and ethics of complete withdrawal of immunosuppression given the very good results achievable with current immunosuppression. Despite these barriers, a number of investigators have continued to conduct well-designed and carefully supervised studies with the long-term goal of making clinical transplantation tolerance more feasible. The aim of this review is to summarize the status of these studies.

Billingham RE, Brent L, Medawar PB (1953) "Actively acquired tolerance" of foreign cells. Nature 172:603–606PubMedCrossRef

Owens ML, Maxwell JG, Goodnight J, Wolcott MW (1975) Discontinuance of immunosuppression in renal transplant patients. Arch Surg 110(12):1450–1451PubMedCrossRef

Zoller KM, Cho SI, Cohen JJ, Harrington JT (1980) Cessation of immunosuppressive therapy after successful transplantation: a national survey. Kidney Int 18(1):110–114PubMedCrossRef

Kingsley CI, Nadig SN, Wood KJ (2007) Transplantation tolerance: lessons from experimental rodent models. Transpl Int 20(10):828–841PubMedCrossRef

Lerut J, Sanchez-Fueyo A (2006) An appraisal of tolerance in liver transplantation. Am J Transplant 6(8):1774–1780PubMedCrossRef

Roussey-Kesler G, Giral M, Moreau A, Subra JF, Legendre C, Noel C et al (2006) Clinical operational tolerance after kidney transplantation. Am J Transplant 6(4):736–746PubMedCrossRef

Halloran PF, Bromberg J, Kaplan B, Vincenti F (2008) Tolerance versus immunosuppression: a perspective. Am J Transplant 8(7):1365–1366PubMedCrossRef

Ballet C, Roussey-Kesler G, Aubin JT, Brouard S, Giral M, Miqueu P et al (2006) Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 6(11):2796–2801PubMedCrossRef

Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G (2008) The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 20(1–2):43–47PubMedCrossRef

10.

Tzakis A, Tryphonopoulos P, Weppler D, Garcia-Morales R, Cirocco R, Sornaraz A et al (2008) Operational tolerance: long term observations after complete withdrawal of immunosuppression (ISP) in liver transplant recipients. Am J Transplant 8(Supplement 2):542

11.

Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J et al (1998) Prope tolerance, perioperative campath 1 H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351(9117):1701–1702PubMedCrossRef

12.

Knechtle SJ, Pascual J, Bloom DD, Torrealba JR, Jankowska-Gan E, Burlingham WJ et al (2009) Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 9(5):1087–1098PubMedCrossRef

13.

Nikolich-Zugich J, Slifka MK, Messaoudi I (2004) The many important facets of T-cell repertoire diversity. Nat Rev Immunol 4(2):123–132PubMedCrossRef

14.

Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA (2001) Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 166(2):973–981PubMed

15.

Ford ML, Koehn BH, Wagener ME, Jiang W, Gangappa S, Pearson TC et al (2007) Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 204(2):299–309, Epub 2007 Jan 29PubMedCrossRef

16.

Valujskikh A, Pantenburg B, Heeger PS (2002) Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2(6):501–509PubMedCrossRef

17.

Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM et al (2003) Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111(12):1887–1895PubMed

18.

Pantenburg B, Heinzel F, Das L, Heeger PS, Valujskikh A (2002) T cells primed by Leishmania major infection cross-react with alloantigens and alter the course of allograft rejection. J Immunol 169(7):3686–3693PubMed

19.

Welsh RM, Markees TG, Woda BA, Daniels KA, Brehm MA, Mordes JP et al (2000) Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 74(5):2210–2218PubMedCrossRef

20.

Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL et al (2005) Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5(3):465–474PubMedCrossRef

21.

Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X et al (2004) Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10(1):87–92PubMedCrossRef

22.

Najafian N, Albin MJ, Newell KA (2006) How can we measure immunologic tolerance in humans? J Am Soc Nephrol 17(10):2652–2663, Epub 006 Aug 23PubMedCrossRef

23.

Newell KA, Larsen CP (2006) Tolerance assays: measuring the unknown. Transplantation 81(11):1503–1509PubMedCrossRef

24.

Marder BA, Schroppel B, Lin M, Schiano T, Parekh R, Tomer Y et al (2003) The impact of costimulatory molecule gene polymorphisms on clinical outcomes in liver transplantation. Am J Transplant 3(4):424–431PubMedCrossRef

25.

Hricik DE, Rodriguez V, Riley J, Bryan K, Tary-Lehmann M, Greenspan N et al (2003) Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 3(7):878–884PubMedCrossRef

26.

Lee PC, Zhu L, Terasaki PI, Everly MJ (2009) HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88(4):568–574PubMedCrossRef

27.

Flechner SM, Kurian SM, Head SR, Sharp SM, Whisenant TC, Zhang J et al (2004) Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 4(9):1475–1489PubMedCrossRef

28.

Li B, Hartono C, Ding R, Sharma VK, Ramaswamy R, Qian B et al (2001) Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 344(13):947–954PubMedCrossRef

29.

Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K et al (2004) Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 15(1):219–227PubMedCrossRef

30.

Gagne K, Brouard S, Giral M, Sebille F, Moreau A, Guillet M et al (2000) Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol 164(3):1553–1563PubMed

31.

Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M et al (2003) Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17(2):77–88PubMedCrossRef

32.

Cortesini R, Renna-Molajoni E, Cinti P, Pretagostini R, Ho E, Rossi P et al (2002) Tailoring of immunosuppression in renal and liver allograft recipients displaying donor specific T-suppressor cells. Hum Immunol 63(11):1010–1018PubMedCrossRef

33.

Sykes M (2007) Immune tolerance: mechanisms and application in clinical transplantation. J Intern Med 262(3):288–310PubMedCrossRef

34.

Agarwal A, Shen LY, Kirk AD (2008) The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Transpl Immunol 20(1–2):6–11PubMedCrossRef

35.

Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL et al (2003) Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1 H). Transplantation 76(1):120–129PubMedCrossRef

36.

Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB (1999) Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5(11):1298–1302PubMedCrossRef

37.

Li Y, Zheng XX, Li XC, Zand MS, Strom TB (1998) Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 66(10):1387–1388PubMedCrossRef

38.

Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9(5):324–337PubMedCrossRef

39.

Li XC, Rothstein DM, Sayegh MH (2009) Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 229(1):271–293PubMedCrossRef

40.

Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C et al (1996) Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381(6581):434–438PubMedCrossRef

41.

Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS et al (1997) CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 94:8789–8794PubMedCrossRef

42.

Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL et al (1999) Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 96(14):8132–8137PubMedCrossRef

43.

Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E et al (2005) Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 5(3):443–453PubMedCrossRef

44.

Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G et al (2005) Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353(8):770–781PubMedCrossRef

45.

Weaver TA, Charafeddine AH, Agarwal A, Turner AP, Russell M, Leopardi FV et al (2009) Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 15(7):746–749PubMedCrossRef

46.

Sykes M (2009) Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials. Transplantation 87(3):309–316PubMedCrossRef

47.

Wekerle T, Sayegh MH, Hill J, Zhao Y, Chandraker A, Swenson KG et al (1998) Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 187(12):2037–2044PubMedCrossRef

48.

Kawai T, Cosimi AB, Colvin RB, Powelson J, Eason J, Kozlowski T et al (1995) Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 59(2):256–262PubMed

49.

Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL et al (2008) HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 358(4):353–361PubMedCrossRef

50.

Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA et al (2008) Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 358(4):362–368PubMedCrossRef

51.

Jones ND, Turvey SE, Van Maurik A, Hara M, Kingsley CI, Smith CH et al (2001) Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J Immunol 166(4):2824–2830PubMed

52.

Zhang Z, Zhu L, Quan D, Garcia B, Ozcay N, Duff J et al (1996) Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. Transplantation 62:1267–1272PubMedCrossRef

53.

Lozano JJ, Pallier A, Martinez-Llordella M, Lopez M, Soulillou JP, Brouard S et al (2010) Absence of significant overlap in blood transcriptional patterns between operationally tolerant liver and kidney recipients. Am J Transplant 10(Supplement 4):193

54.

Mazariegos GV, Sindhi R, Thomson AW, Marcos A (2007) Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 17(2):114–119PubMedCrossRef

55.

Mazariegos GV, Reyes J, Marino IR, Demetris AJ, Flynn B, Irish W et al (1997) Weaning of immunosuppression in liver transplant recipients. Transplantation 63(2):243–249PubMedCrossRef

56.

Koshiba T, Li Y, Takemura M, Wu Y, Sakaguchi S, Minato N et al (2007) Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 17(2):94–97PubMedCrossRef

57.

Yoshitomi M, Koshiba T, Haga H, Li Y, Zhao X, Cheng D et al (2009) Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 87(4):606–614PubMedCrossRef

58.

Tryphonopoulos P, Tzakis AG, Weppler D, Garcia-Morales R, Kato T, Madariaga JR et al (2005) The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 5(3):608–613PubMedCrossRef

59.

Martinez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A et al (2007) Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 7(2):309–319PubMedCrossRef

60.

Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G, Tisone G, Lerut J et al (2008) Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 118(8):2845–2857PubMed

61.

Puig-Pey I, Bohne F, Benitez C, Lopez M, Martinez-Llordella M, Oppenheimer F et al (2010) Characterization of gammadelta T cell subsets in organ transplantation. Transpl Int 23(10):1045–1055PubMedCrossRef

62.

Millan O, Benitez C, Guillen D, Lopez A, Rimola A, Sanchez-Fueyo A et al (2010) Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol 137(3):337–346PubMedCrossRef

63.

Seyfert-Margolis V, Feng S (2010) Tolerance: is it achievable in pediatric solid organ transplantation? Pediatr Clin North Am 57(2):523–538PubMedCrossRef

64.

Starzl TE, Demetris AJ, Trucco M (1993) Chimerism and donor specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 55:1272–1277PubMedCrossRef

65.

VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, Chin T, Kusaka S, Geissler F et al (2000) Human allograft acceptance is associated with immune regulation. J Clin Invest 106(1):145–155PubMedCrossRef

66.

Brouard S, Dupont A, Giral M, Louis S, Lair D, Braudeau C et al (2005) Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 5(2):330–340PubMedCrossRef

67.

Baeten D, Louis S, Braud C, Braudeau C, Ballet C, Moizant F et al (2006) Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 17(1):294–304, Epub 2005 Dec 7PubMedCrossRef

68.

Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N et al (2006) Contrasting CD25hiCD4 + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 81(3):398–407PubMedCrossRef

69.

Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC et al (2007) Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 104(39):15448–15453, Epub 2007 Sep 14PubMedCrossRef

70.

Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M et al (2010) Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 120(6):1836–1847PubMedCrossRef

71.

Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P et al (2010) Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120(6):1848–1861PubMedCrossRef

72.

Liu C, Noorchashm H, Sutter JA, Naji M, Prak EL, Boyer J et al (2007) B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 13(11):1295–1298PubMedCrossRef

73.

Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 10(4):236–247PubMedCrossRef

74.

Pallier A, Hillion S, Danger R, Giral M, Racape M, Degauque N et al (2010) Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 78(5):503–513PubMedCrossRef

75.

Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F et al (2006) Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 6(9):2121–2133, Epub 006 Jun 22PubMedCrossRef

76.

Mazariegos GV, Zahorchak AF, Reyes J, Chapman H, Zeevi A, Thomson AW (2005) Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 5(2):314–322PubMedCrossRef

77.

Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A et al (2004) Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 4(12):2118–2125PubMedCrossRef

Title: Clinical transplantation tolerance
Author: Kenneth A. Newell
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 2/2011
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-011-0255-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Transplantation and tolerance

Role of Th17 cells and IL-17 in lung transplant rejection

Inflammation and transplantation tolerance

Loss of tolerance to self after transplant

Special issues in the management and selection of the donor for lung transplantation

Assessment of kidney organ quality and prediction of outcome at time of transplantation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials